Addition of ET(A) receptor blockade increases renoprotection provided by renin-angiotensin system blockade in 5/6 nephrectomized Ren-2 transgenic rats
Jazyk angličtina Země Nizozemsko Médium print-electronic
Typ dokumentu časopisecké články, práce podpořená grantem
PubMed
24373834
DOI
10.1016/j.lfs.2013.12.018
PII: S0024-3205(13)00775-3
Knihovny.cz E-zdroje
- Klíčová slova
- 5/6 nephrectomy, Chronic kidney disease, End-organ damage, Endothelin receptor type A, Hypertension,
- MeSH
- angiotensin II krev MeSH
- antagonisté endotelinového receptoru terapeutické užití MeSH
- endotelin-1 metabolismus MeSH
- kardiomegalie krev komplikace farmakoterapie patologie MeSH
- krevní tlak účinky léků MeSH
- ledviny účinky léků patologie patofyziologie MeSH
- nefrektomie * MeSH
- nemoci ledvin krev komplikace farmakoterapie patologie MeSH
- ochranné látky farmakologie terapeutické užití MeSH
- potkani Sprague-Dawley MeSH
- potkani transgenní MeSH
- receptor endotelinu A metabolismus MeSH
- renin-angiotensin systém účinky léků MeSH
- renin genetika MeSH
- systola účinky léků MeSH
- zvířata MeSH
- Check Tag
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Názvy látek
- angiotensin II MeSH
- antagonisté endotelinového receptoru MeSH
- endotelin-1 MeSH
- ochranné látky MeSH
- receptor endotelinu A MeSH
- Ren2 protein, rat MeSH Prohlížeč
- renin MeSH
AIMS: There is evidence that in addition to hypertension and hyperactivity of the renin-angiotensin system (RAS), enhanced intrarenal activity of endothelin (ET) system contributes to the pathophysiology and progression of chronic kidney disease (CKD). This prompted us to examine if this progression would be alleviated by addition of type A ET receptor (ETA) blockade to the standard blockade of RAS. MAIN METHODS: Ren-2 transgenic rats (TGR) after 5/6 renal ablation (5/6 NX) served as a model of CKD. For RAS inhibition a combination of angiotensin-converting enzyme inhibitor (trandolapril, 6 mg/L drinking water) and angiotensin II type 1 receptor blocker (losartan, 100 mg/L drinking water) was used. Alternatively, ETA receptor blocker (atrasentan, 5 mg·kg(-1)·day(-1) in drinking water) was added to the combined RAS blockade. The follow-up period was 44 weeks after 5/6 NX, and the rats' survival rate, systolic blood pressure (SBP), proteinuria and indices of renal glomerular damage were evaluated. KEY FINDINGS: The survival rate was at first improved, by either therapeutic regime, however, the efficiency of RAS blockade alone considerably decreased 36 weeks after 5/6 NX: final survival rate of 65% was significantly lower than 91% achieved with combined RAS and ETA receptor blockade. SBP was not affected by the addition of ETA blockade while proteinuria and renal glomerular damage were further reduced. SIGNIFICANCE: Our data show that a combined RAS and ETA receptor blockade exhibits additional beneficial effects on survival rate and the progression of CKD in 5/6 NX TGR, as compared with RAS inhibition alone.
Department of Nephrology 1st Faculty of Medicine Charles University Prague Czech Republic
Department of Pathology 3rd Faculty of Medicine Charles University Prague Czech Republic
Institute of Physiology v v i Academy of Sciences of the Czech Republic Prague Czech Republic
Section of Nephrology Medical Policlinic Department of Medicine University of Bonn Bonn Germany
Citace poskytuje Crossref.org
Altered Balance between Vasoconstrictor and Vasodilator Systems in Experimental Hypertension